StreetInsider.com News Articles

Moderna shares continue to fall after early cancer vaccine data leak

Fri, 23 Oct 2026 09:50:17 -0400

Moderna Inc. shares dropped 2.3% in morning trading on Friday, adding to sharp losses from the previous session after clinical trial results for its personalized melanoma vaccine were published early by a medical news website on Thursday.

The Phase 3 data for intismeran autogene, developed with Merck & Co. (NYSE:MRK), was scheduled for presentation at the ESMO Congress in Madrid on Saturday. The information appeared on a medical news website Thursday afternoon before being removed, prompting Moderna and Merck to issue an official release of the results.

The INTerpath-001 trial showed the vaccine combined with Merck's Keytruda reduced the risk of melanoma

Moderna shares continue to fall after early cancer vaccine data leak

Fri, 23 Oct 2026 09:50:17 -0400

The INTerpath-001 trial showed the vaccine combined with Merck's Keytruda reduced the risk of melanoma

Citi reiterates Sell rating on Moderna with $80 price target

Fri, 23 Oct 2026 09:48:42 -0400

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA).

Meacham outlined ten reasons why positive melanoma trial data from the INTerpath-001 study do not address his concerns about the company's valuation. He noted that one successful study in melanoma does not validate individualized neoantigen therapy as a broadly applicable oncology platform, and that overall survival data remain immature.

The analyst said the therapy, intismeran, requires tumor sequencing, individualized manufacturing, and coordination across multiple medical disciplines, with pricing still unknown. He also pointed to neoadjuvant pembrolizumab as a simpler alternative, citing an event-free survival hazard ratio

Moderna Named a Top Employer by Science for Twelfth Consecutive Year

Fri, 23 Oct 2026 07:00:00 -0400

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.

"At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and

Moderna Named a Top Employer by Science for Twelfth Consecutive Year

Fri, 23 Oct 2026 07:00:00 -0400

"At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and

Moderna (MRNA) call put ratio 1 call to 1.4 puts amid wide share price movement

Fri, 23 Oct 2026 05:51:06 -0400

Moderna (NASDAQ: MRNA) 30-day option implied volatility is at 92; compared to its 52-week range of 57 to 138. Call put ratio 1 call to 1.4 puts amid wide share price movement.

RBC Capital Reiterates Sector Perform Rating on Merck (MRK)

Thu, 22 Oct 2026 16:05:11 -0400

RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $145.00 price target on Merck (NYSE: MRK).

The analyst comments "Our View: The INTerpath-001 data is clinically meaningful and likely approvable, offering patients an important new treatment option in high-risk melanoma. An RFS hazard ratio of 0.58 with a well-tolerated safety profile should support regulatory filings in the US and Europe, and we expect FDA approval in 2027. Merck and Moderna are currently engaging with regulatory authorities. However, the data falls short of the high bar set by Phase 2 results and investor expectations. Going into the readout, investor expectations

RBC Capital Reiterates Sector Perform Rating on Merck (MRK)

Thu, 22 Oct 2026 16:05:11 -0400

RBC Capital analyst Trung Huynh reiterated a Sector Perform rating and $145.00 price target on Merck (NYSE: MRK).

Citi keeps Sell rating on Moderna after melanoma trial data, PT $80

Thu, 22 Oct 2026 16:01:44 -0400

Citi analyst Geoff Meacham reiterated a Sell rating and $80.00 price target on Moderna (NASDAQ: MRNA) after phase 3 INTerpath-001 trial data showed the company's intismeran combined with pembrolizumab reduced the risk of recurrence or death by 42% compared to pembrolizumab alone in adjuvant melanoma, with a hazard ratio of 0.58.

Moderna shares fell 25% intraday following the data release, which was confirmed by the European Society for Medical Oncology. The broader XBI index and S&P 500 each declined approximately 1% on the same day.

Meacham noted that while the trial results represent a clinically meaningful advance with consistent efficacy across lower-

Merck and Moderna report Phase 3 melanoma trial results